2018-000373-80: A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Safety and Efficacy of LX3305, a Sphingosine-1-Phosphate Lyase Inhibitor, for Treatment of Darier’s Disease or Hailey-Hailey Disease |
|
|
| Ongoing | 1/2 | 40 | Europe | LX3305 250 mg capsule, LX3305, Capsule | Dermecular Therapeutics, Inc., Dermecular Therapeutics, Inc. | Darier’s Disease or Hailey-Hailey Disease, Darier’s Disease or Hailey-Hailey Disease, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
